Colombo, Marco
,
Valo, Erkka
McGurnaghan, Stuart J.
Sandholm, Niina
Blackbourn, Luke A. K.
Dalton, R. Neil
Dunger, David
Groop, Per-Henrik
McKeigue, Paul M.
Forsblom, Carol
Colhoun, Helen M. http://orcid.org/0000-0002-8345-3288
Funding for this research was provided by:
Chief Scientist Office (ETM/47)
Helsinki University Hospital Research Funds
The Academy of Finland (275614)
The Wilhelm and Else Stockmann Foundation
Novo Nordisk Foundation
The Liv och Hälsa Society
Diabetes UK (10/0004010)
Folkhälsan Research Foundation
Juvenile Diabetes Research Foundation (1-SRA-2016-333-M-R)
Article History
Received: 27 February 2019
Accepted: 30 April 2019
First Online: 20 June 2019
Duality of interest
: P-HG has received investigator research grants from Eli Lilly and Roche, and lecture honoraria from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Elo Water, Genzyme, MSD, Novartis, Novo Nordisk and Sanofi. P-HG is an advisor for AbbVie, AstraZeneca, Boehringer Ingelheim, Cebix, Eli Lilly, Janssen, MSD, Novartis, Novo Nordisk and Sanofi.
: HMC receives research support and honorarium and is also a member of the advisory panels and speaker’s bureaus for Sanofi Aventis, Regeneron and Eli Lilly. HMC has been a member of Data and Safety Monitoring Board of the Advisory Panel for the CANTOS Trial (Novartis Pharmaceuticals). HMC also receives or has recently received a non-binding research support from Pfizer Inc. and AstraZeneca LP. HMC is a shareholder of Roche Pharmaceuticals and Bayer.
: RND is a shareholder of SpOtOn Clinical Diagnostics Ltd.
: MC, EV, SJM, NS, LAKB, DD, PMM and CF declare that there is no duality of interest associated with their contribution to this manuscript.